Biotransformation enzymes for xenobiotics and personalization of treatment regimens for tuberculosis patients

Abstract

The article presents the analysis of the literature on specific metabolism of anti-tuberculosis drugs depending on polymorphism of genes controlling synthesis and action of biotransformation enzymes, in particular cytochrome P-450 isozymes and enzymes of the IInd phase of biotransformation (N-acetyltransferase, glutathione S-transferase) respective adverse reactions development, first of all hepatotoxic ones. The possibility of pharmacogenetic studies with the evaluation of genetic predisposition to developing adverse reactions to medications has been discussed in respect of personalized approach to effective and safe treatment of tuberculosis patients.

Keywords

• туберкулез
• противотуберкулезные препараты
• персонифицированный подход к лечению
• ферменты биотрансформации ксенобиотиков
• типы ацетилирования
• фармакогенетика
• полиморфизм генов ферментов биотрансформации ксенобиотиков